Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor
Stammler, A.; Vielhaber, K.
Fortschritte der Neurologie Psychiatrie und Ihrer Grenzgebiete 40(10): 564-568
1972
ISSN/ISBN: 0015-8194 PMID: 4565521 Document Number: 57006
Document emailed within 1 workday
Related Documents
Fischer, P.A.; Schneider, E.; Jacobi, P.; Maxion, H. 1973: Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor Die Medizinische Welt 24(45): 1742-1746De Divitiis, E.; Cerillo, A.; Tata, M.R.; Decina, A. 1973: Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results Acta Neurologica 28(2): 208-212
Wajsbort, J.; Hemli, J.A.; Alfandary, I.; Yahel, M.; Siegfried, J. 1971: Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association Wiener Medizinische Wochenschrift 121(42): 741-745
Eisenlohr, J.J.; Gehlen, W. 1975: Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor) Der Nervenarzt 46(3): 128-135
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Matussek, N.; Benkert, O.; Schneider, K.; Otten, H.; Pohlmeier, H. 1970: Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions Arzneimittel-Forschung 20(7): 934-935
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713
Rabadeau Dumas, J.L.; Rondot, P.; Cardon, P. 1977: Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor Therapie 32(2): 161-172
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Pontiroli, A.E.; Castegnaro, E.; Vettaro, M.P.; Viberti, G.C.; Pozza, G. 1977: Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine Acta Endocrinologica 84(1): 36-44
Geissbuhler, F.; Eisenring, J.J.; Friedli, P.; Bartholini, G.; Tissot, R. 1972: Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects L'Encephale 61(2): 127-148
Danielczyk, W.; Korten, J.J. 1971: Action of amantadine HCl alone and in combination with L-dopa on parkinsonism Medizinische Monatsschrift 25(10): 472-479
Eisenlohr, J.J.; Gehlen, W. 1974: Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) Münchener Medizinische Wochenschrift 116(28): 1353-1356
Jörg, J. 1975: Therapy of parkinsonism using L-Dopa (Brocadopa) Die Medizinische Welt 26(3): 124-126
Bhaskar, P.A.; Bhaskar, E.A.; Jagannathan, K. 1975: Augmenting procedures during L-dopa therapy for Parkinsonism Journal of the Association of Physicians of India 23(1): 21-27
Marjerrison, G.; Boulton, A.A.; Rajput, A. 1971: Dopa therapy in parkinsonism effects on the EEG and amine metabolism Internationale Zeitschrift für Klinische Pharmakologie Therapie und Toxikologie. International Journal of Clinical Pharmacology Therapy and Toxicology 4(2): 263-266
Yahr, M.D.; Duvoisin, R.C.; Mendoza, M.R.; Schear, M.J.; Barrett, R.E. 1971: Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486) Transactions of the American Neurological Association 96: 55-58
Blair, M.L.; Reid, I.A.; Ganong, W.F. 1977: Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs Journal of Pharmacology and Experimental Therapeutics 202(1): 209-215
Matussek, N.; Angst, J.; Benkert, O.; Gmür, M.; Papousek, M.; Rüther, E.; Woggon, B. 1974: The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients Advances in Biochemical Psychopharmacology 11: 399-404